Request Call Back

Contact Us

Defective Drugs
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



   * Name of drug: 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Lamictal Birth Defects

Lamictal Lawsuit | Side Effects : Birth Defects, Cleft Lip, Cleft Palate Lamictal Lawsuit | Lawsuits, Lawyer, Attorney | Side Effects: Birth Defects, Cleft Lip, Cleft Palate

Lamictal Lawsuit | Side Effects : Birth Defects, Cleft Lip, Cleft Palate

Lamictal Lawsuit | Lawsuits, Lawyer, Attorney | Side Effects: Birth Defects, Cleft Lip, Cleft Palate

Lamictal Birth Defects Reported to the FDA

In September 2011, AdverseEvents, Inc. reported that its analysis of the FDA's Adverse Event Reporting System (AERS) indicated that Lamictal was more dangerous to unborn babies than previously thought. The analysis indicated that moving Lamictal from its current FDA pregnancy risk class, Category C (“no known human risk”), to Category D (“positive evidence of human fetal risk") could be warranted.

In conducting its analysis, AdverseEvents used a proprietary process called RxFilter to analyze the FDA’s AERS database for treatment-related birth defects, stillbirths and congenital abnormalities potentially associated with 18 anti-epilepsy medications, including Lamictal, that are commonly prescribed during pregnancy. The time period covered by the AdverseEvents analysis was January 1, 2004 to March 31, 2011.

Lamictal Birth Defects Reported : Babies exposed to Lamictal during the first three months of pregnancy might have a higher chance of being born with a cleft lip or cleft palate

According to AdverseEvents, an average birth defect rate comparison between Lamictal and top Category D drugs yielded a surprising result; no meaningful differences were found. "These results indicate that regulatory bodies may want to consider category shifts for some of the most widely used antiepilepsy medications. Prospective studies, however, are needed to establish the exact incidence of these adverse events and to determine appropriate changes in category labeling, if any. This analysis warrants the attention of all healthcare providers and patients associated with epilepsy medications," a statement from AdverseEvents said.

On September 29, 2006, the FDA notified healthcare professionals and patients of new information from the North American Antiepileptic Drug Pregnancy Registry signifying that babies exposed to Lamictal, designated to treat seizures and bipolar disorder, during the first three months of pregnancy might have a higher chance of being born with a cleft lip or cleft palate. Women who are pregnant and are taking Lamictal or who are thinking about taking this medication are strongly urged to not start or stop taking the medication without first talking to their physician. More research is needed to be sure about the possibility of the increased chance of cleft lip or cleft palate developing in babies of pregnant women who take Lamictal.

On August 8, 2006 drug manufacturer GlaxoSmithKline warned pregnant women of the potential association between the drug Lamictal (generic: lamotrigine) and cleft palate or cleft lip in newborns. Lamictal gained FDA (Food & Drug Association) approval in 1994 and was approved by Health Canada in 1995. Lamictal is prescribed to combat epilepsy.

GlaxoSmithKline in conjunction with Health Canada stated that new statistics from a pregnancy registry recommend a correlation between taking Lamictal during the first trimester of pregnancy, and increased risk of cleft lip and/or palate in the baby. Based upon data from the public oral clefts is one of the most ordinary major birth defects, occurring at rates of 0.5 to 2.16 per 1,000 births. Data from the pregnancy registry illustrated three cases of cleft palate and two cases of cleft lip in infants born to 564 users Lamictal, a rate of 8.9 per 1,000.

Current patients taking Lamictal have been instructed to alert their doctors if they become pregnant or intend to become pregnant. Immediate stoppage of anti-eplieptic therapy may lead to breakthrough seizures with can cause serious risks for both the mother and the fetus and should be avoided. Peter Schram, a spokesman for GlaxoSmithKline, said other discontinuation symptoms could include rashes, dizziness, headaches, nausea and blurred vision.

Legal Help For Victims Affected By Lamictal

If you or a loved one has taken Lamictal while pregnant and you infant was born with a birth defect, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or call us at 1-800-YOURLAWYER (1-800-968-7529).


Lamictal Birth DefectsRSS Feed

Lamictal May Cause Meningitis, FDA Warns

Aug 12, 2010 | Parker Waichman LLP
Lamictal (lamotrigine), a treatment for seizures and bipolar disorder marketed by GlaxoSmithKline, can cause aseptic meningitis, the US Food & Drug Administration (FDA) warned today. The agency said it is working with Glaxo to update the Warnings and Precautions section of the prescribing information and the patient medication guide for Lamictal to include this risk. Meningitis is an inflammation of the protective membranes (the meninges) that cover the brain and spinal cord. Aseptic...

Epilepsy Drugs to Carry Suicide Warnings

Dec 17, 2008 | Parker Waichman LLP
Epilepsy drugs must now carry warnings about their suicide risks, the Food & Drug Administration (FDA) has announced.  The drugs subject to the new warning include those used to treat psychiatric disorders, migraine headaches and other conditions, as well as epilepsy.  Epilepsy drugs on the list are:Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, Tegretol XR) Clonazepam (marketed as Klonopin) Clorazepate (marketed as Tranxene) Divalproex sodium (marketed as Depakote,...

Epilepsy Drugs Targeted for Black Box Suicide Warning

Jul 8, 2008 | Parker Waichman LLP
Federal regulators want the makers of epilepsy drugs to add a black box warning to their labels about their association with suicidal thoughts and behavior. The Food & Drug Administration (FDA) is set to ask an outside advisory panel for its recommendations on the proposed black box at a meeting this Thursday.   In total, 11 epilepsy drugs could get the new black box warning - the FDA's strongest safety notice. They include: Carbamazepine (marketed as Carbatrol, Equetro,...

New Suicide Warning for Epilepsy Drugs

Jun 12, 2008 | Parker Waichman LLP
United States drug reviewers just announced that epilepsy drugs are associated with a higher risk of suicidal thoughts and behavior.  The analysis was released this week and confirmed earlier findings.  "The effect appears consistent among the group of 11 drugs" that were reviewed, according to a summary from statistical reviewers at the Food and Drug Administration (FDA).  In the review dated May 23, the FDA staff said that there were about two more cases of suicidal thoughts...

Epilepsy Drugs to Get Suicide Warnings, FDA Confirms

Jun 6, 2008 | Parker Waichman LLP
US regulators are very close to finalizing new suicide warnings for 11 epilepsy drugs, The Wall Street Journal reported today.  This past January, the Food & Drug Administration (FDA) issued an Early Communication announcing a safety review of the epilepsy drugs after a study showed they increased patients' risk of suicidal thoughts and behavior. The 11 epilepsy drugs slated for a new suicide warning are: Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, Tegretol XR)...

More Lamictal Birth Defects News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo